Dry eye disease,
a well-known “civilization disease”
Launched more than 20 years ago, our hyaluronic acid-based lubricant eye drops meet high compliance and patient satisfaction.
Affecting between 5% and 34% of people worldwide, Dry eye disease represents a significant economic burden due to direct and indirect healthcare costs such as reduced work productivity.1,2,3 We have developed the VISMED® range of lubricant eye drops consisting in hypo-osmolar sodium hyaluronate solutions indicated for the treatment of symptoms and signs of dry eye, ocular surface damage and eye irritation due to different diseases such as superficial keratitis, Sjögren’s syndrome, or primary dry eye syndrome.4-6 The VISMED® product range has been formulated in order to break the vicious cycle of dry eye by counteracting tear hyperosmolarity and stabilising the tear film.7 With a choice of sodium hyaluronate concentrations varying from 0.1% to 0.3%, we offer an adaptable range of concentrations to meet the patient’s specific needs.
Ophthalmologic surgical relief
Patients can benefit from TRB Chemedica experience and products with proven efficacy and safety by reducing complications during or after cataract surgery.
Cataract surgery is among the most common and most successful surgical procedures performed today.8 VISIOL®, a sodium hyaluronate solution containing mannitol has been developed by our team to improve protection against endothelial damage and to preserve tissue integrity and provide good visibility during surgery of the anterior segment of the eye such as cataract surgery, intraocular lens implantation, corneal transplantation surgery and glaucoma filtering surgery. 9-10 Easy product handling during the surgery allows a quick and safe surgery with an optimal outcome for the patients.10
- Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112(5):71-81.
- Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15:334-65.
- Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118(9):1264-8.
- Vismed European instructions for use, last revision date: April 2012
- Vismed Gel European instructions for use, last revision date: September 2015
- Vismed Light European instructions for use, last revision date: September 2016
- Montes-Mico R, Caliz A, Alio JL. Changes in ocular aberrations after instillation of artificial tears in dry-eye patients. J Cataract Refract Surg. 2004;30:1649-52.
- Nguyen J & Werner L. (2017). Intraocular lenses for cataract surgery. In: Kolb H, Fernandez E, Nelson R, editors. Webvision: The Organization of the Retina and Visual System [Internet]. Salt Lake City, UT: University of Utah Health Sciences Center.
- Belda JI, Artola A, García-Manzanares MD, Ferrer C, Haroun HE, et al. Hyaluronic acid combined with mannitol to improve protection against free-radical endothelial damage: experimental model. J Cataract Refract Surg. 2005;31(6):1213-8
- Visiol European instructions for use, last revision date: June 2013